Lancet Study Looks into Reasons for Lipitor Diabetes Risk

Published on October 1, 2014 by Sandy Liebhard

Text-Size:A A A+

 

People taking statin medications to lower their cholesterol may be 12 percent more likely to develop Type 2 diabetes, a link now alleged in Lipitor lawsuit filings, and gain half a pound of weight over four years, a new study finds.

Research led by a team at the University College London and the University of Glasgow came to this conclusion after looking at generic data from 223,463 individuals, and 129,170 people who participated in clinical trials that measured the effect of statins on heart disease and stroke. Findings were recently published in The Lancet, according to a WebMD.com article posted on September 24th.

A co-author of the study, who hails from the University of Glasgow Institute of Cardiovascular and Medical Sciences, pointed out that heavier people may be more likely to develop diabetes, which counts weight gain as a known risk factor. This “might help explain the small increased risk of diabetes observed in people taking statins,” he said.

Statin Study Highlights Benefits of Lipitor and other Drugs, Leaders Say

An associate medical director at the British Heart Foundation defended the safety of statins, which he stressed are beneficial to people looking to lower levels of LDL or “bad” cholesterol.

“This study should reassure people that the benefits of taking statins far outweigh the small effect on diabetes risk. But the results also reinforce that, alongside prescribed medication, taking steps to maintain a healthy weight is essential to stay heart healthy,” he said.

The safety of Lipitor and other statins has been scrutinized for the past few years, however, amid a mandated drug label change from the U.S. Food and Drug Administration (FDA) that required manufacturers to warn about their products’ possible association with diabetes. Since then, more and more lawsuits alleging Lipitor diabetes injuries have been consolidated in a federal multidistrict litigation (MDL) established for Lipitor-related claims. This proceeding is currently underway in the U.S. District Court, District of South Carolina, and included at least 1,279 claims in September.

These claims allege that Lipitor’s newly adjusted label remains insufficient in warning people about its association with diabetes, and that Pfizer Inc. was negligent in designing, manufacturing and marketing a medication that is defective.

Consider a Lipitor Lawsuit

Contact our Firm for more about Lipitor lawsuits. If you took this medication to lower your cholesterol, you may be eligible to file a claim: .